{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Approved Allergenic Extract
(1975)
Source:
BLA103753
(1975)
Source URL:
First approved in 1941
Source:
BLA103888
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
MoistiMed Anti-Acne Mask by M&T Pharmaceutical Technology Co.,LTD
(2024)
Source URL:
First approved in 2024
Source:
MoistiMed Anti-Acne Mask by M&T Pharmaceutical Technology Co.,LTD
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2023)
Source URL:
First approved in 2023
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M005
(2023)
Source URL:
First approved in 2023
Source:
M005
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2023
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2021)
Source URL:
First approved in 2021
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 341
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 341
Source URL:
Class:
STRUCTURALLY DIVERSE